ID

14960

Description

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase; ODM derived from: https://clinicaltrials.gov/show/NCT00528281

Lien

https://clinicaltrials.gov/show/NCT00528281

Mots-clés

  1. 09/05/2016 09/05/2016 -
Téléchargé le

9 mai 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
Written informed consent
Description

informed consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
patients must be 18 years old
Description

age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
subjects must have stage iiib or iv nsclc
Description

nsclc

Type de données

boolean

Alias
UMLS CUI [1]
C0007131
recurrent or persistent nsclc following one previous line of cytotoxic chemotherapy
Description

cytotoxic chemotherapy

Type de données

boolean

Alias
UMLS CUI [1]
C0677881
eastern cooperative oncology group (ecog) performance status (ps) 0-2;
Description

ecog

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of 12 weeks
Description

life expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
have adequate organ function baseline laboratory values for inclusion
Description

organ function

Type de données

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of other malignancy. subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
Description

malignancy

Type de données

boolean

Alias
UMLS CUI [1]
C0455471
known history of or clinical evidence of central nervous system (cns) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated cns metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
Description

central nervous system metastases

Type de données

boolean

Alias
UMLS CUI [1]
C0686377
peripheral neuropathy of grade 3 or higher
Description

peripheral neuropathy

Type de données

boolean

Alias
UMLS CUI [1]
C0031117
concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
Description

cconcurrent ancer therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0205420
UMLS CUI [1,2]
C0920425
prior exposure to pemetrexed or an egfr inhibitor in combination with 5-fu or a 5fu prodrug.
Description

pemetrexed

Type de données

boolean

Alias
UMLS CUI [1]
C0210657

Similar models

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
informed consent
Item
Written informed consent
boolean
C0021430 (UMLS CUI [1])
age
Item
patients must be 18 years old
boolean
C0001779 (UMLS CUI [1])
nsclc
Item
subjects must have stage iiib or iv nsclc
boolean
C0007131 (UMLS CUI [1])
cytotoxic chemotherapy
Item
recurrent or persistent nsclc following one previous line of cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
ecog
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-2;
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy of 12 weeks
boolean
C0023671 (UMLS CUI [1])
organ function
Item
have adequate organ function baseline laboratory values for inclusion
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
malignancy
Item
history of other malignancy. subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
boolean
C0455471 (UMLS CUI [1])
central nervous system metastases
Item
known history of or clinical evidence of central nervous system (cns) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated cns metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
boolean
C0686377 (UMLS CUI [1])
peripheral neuropathy
Item
peripheral neuropathy of grade 3 or higher
boolean
C0031117 (UMLS CUI [1])
cconcurrent ancer therapy
Item
concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
boolean
C0205420 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
pemetrexed
Item
prior exposure to pemetrexed or an egfr inhibitor in combination with 5-fu or a 5fu prodrug.
boolean
C0210657 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial